# Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

> **NCT03875729** · PHASE3 · COMPLETED · sponsor: **Provention Bio, Inc.** · enrollment: 328 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** teplizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03875729
- **Lead sponsor:** Provention Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875729, "Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03875729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*